Scalper1 News
Gilead Sciences beat analysts’ fourth-quarter expectations Tuesday but gave weak 2015 sales guidance, as the biotech suffers pricing pressures on its blockbuster hepatitis C drugs. Earnings leaped 342% to $2.43 a share, 21 cents above the consensus. Revenue jumped 134% to $7.31 billion, more than $500 million above Wall Street’s view. However, Gilead (GILD) sees full-year net product sales of $26 billion to $27 billion, falling below Scalper1 News
Scalper1 News